A Second Blood Test for Colorectal Cancer Arrives — SimpleScreen Joins – Good Machine

TL;DR

The US Food and Drug Administration approved Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged 45 and older in late July 2026 (Freenome press release, FDA approval letter, 30 Jul 2026).
It is the second blood-based colorectal cancer screening test to reach the US market, following Guardant Health's Shield (approved July 2024) (Medical News Today, 4 Aug 2026).
In the PREEMPT CRC pivotal trial of 48,995 asymptomatic adults, SimpleScreen detected colorectal cancer with 81.1% sensitivity and 90.2% specificity for advanced colorectal neoplasia (Freenome PREEMPT CRC data, presented DDW 2025, published 2026).
Sensitivity for advanced precancerous lesions (polyps that have not yet progressed to cancer) was 13.7% — a critical limitation that clinicians say patients need to understand.
The context: colorectal cancer rates are rising roughly 1% per year in Americans under 50. Screening completion among eligible adults sits at approximately 67%. The blood test's role is to close the gap in that other third — not to replace colonoscopy.

What happened

On 30 July 2026, the FDA approved SimpleScreen CRC, a blood-based colorectal cancer screening test developed by South San Francisco-based Freenome. The approval covers average-risk adults aged 45 and older who are not currently up to date on colorectal cancer screening and who are unwilling or unable to undergo other screening options (FDA approval letter, 30 Jul 2026).

SimpleScreen is the second blood test to receive FDA approval for colorectal cancer screening. The first, Guardant Health's Shield, was approved in July 2024 (Medical News Today, 4 Aug 2026). Both tests are approved as first-line screening options — meaning insurers, including Medicare, are required to cover them for eligible patients without cost-sharing under the Affordable Care Act's preventive services provisions.

The regulatory pathway hinged on a large prospective trial. PREEMPT CRC enrolled 48,995 asymptomatic adults aged 45–85 across more than 200 US clinical sites. Participants provided a blood sample and then underwent screening colonoscopy — the reference standard — allowing the test's performance to be measured directly against the gold standard on the same patients (Freenome, PREEMPT CRC pivotal results).

The headline numbers:

Colorectal cancer sensitivity: 81.1%. Of the participants with confirmed colorectal cancer, the blood test correctly identified 81 out of 100.
Specificity for advanced colorectal neoplasia: 90.2%. Of the participants without advanced disease, the test correctly returned negative in about 90 out of 100.
Advanced precancerous lesion sensitivity: 13.7%. Of the participants with advanced adenomas — polyps that have not yet become cancer but are on that trajectory — the test correctly identified only about 14 in 100.

The comparable Shield trial numbers are 83% for colorectal cancer sensitivity and 13% for advanced precancerous lesions — broadly similar performance across the two tests (Guardant Health, ECLIPSE trial data, 2024).

What it actually means

The debate that surrounds these tests is not really about whether they work. On their stated task — detecting existing colorectal cancer in a blood sample — they work at approximately the level the FDA requires. The debate is about what "screening" means, and whether a test that catches cancer well but misses precancerous polyps counts as screening in the same sense that colonoscopy does.

Colonoscopy does two things. It detects cancer, and it prevents cancer by removing adenomatous polyps before they can progress. The prevention effect is where colonoscopy earns most of its mortality-reduction credit. A large body of evidence, including the Nordic-European NordICC trial and long-running US cohort studies, attributes the roughly 50% reduction in colorectal cancer mortality associated with colonoscopy to a combination of early detection and polyp removal.

A blood test can't remove a polyp. And, based on the PREEMPT and ECLIPSE data, it doesn't detect them well either. Memorial Sloan Kettering gastroenterologist Dr Robin Mendelsohn was direct in comments to Medical News Today: "Once the genetic material has made it to the bloodstream, the cancer is much more likely to be invasive and advanced. Screening's job isn't just to find cancer — it's to prevent it. This test doesn't prevent it" (Medical News Today, 4 Aug 2026).

The counter-argument comes from public health rather than gastroenterology. Colorectal cancer screening completion in the eligible US population sits at approximately 67%. That means roughly a third of eligible Americans — some 30 million people — are not screened at all. For that population, the choice is not blood test versus colonoscopy. It is blood test versus nothing (American Cancer Society screening data, 2025).

A test that catches 81% of existing cancers in people who would otherwise be caught only when symptoms drove them to the emergency department is a meaningful improvement over the status quo for that group. The question is whether the test is used that way — as a gateway for the unscreened — or whether it substitutes for colonoscopy in patients who would otherwise complete the more effective screen.

The mechanism

Both SimpleScreen and Shield operate on the same underlying principle: circulating tumour DNA (ctDNA) and other cancer-associated molecular signals shed into the bloodstream by tumours. SimpleScreen's approach layers a multiomic profile — analysing cell-free DNA, methylation patterns, and protein biomarkers together — through a machine-learning classifier trained on tens of thousands of samples (Freenome technical publications).

The multiomic angle is Freenome's technical differentiator relative to Shield's methylation-focused platform, and it is what the company argues gives SimpleScreen an incremental sensitivity edge. Independent head-to-head data does not yet exist. Both tests received FDA approval on their own trial evidence, not against each other.

Why the timing matters

Colorectal cancer incidence in Americans under 50 has been rising for approximately two decades. The American Cancer Society projects colorectal cancer will become the leading cause of cancer death in adults under 50 in the United States by 2030. Incidence in adults aged 20–39 has risen by roughly 2% per year over the past decade. More than 55,000 colorectal cancer deaths are forecast in the US in 2026 (American Cancer Society Cancer Facts & Figures 2026).

The 2021 update to US Preventive Services Task Force guidelines moved the recommended screening start age from 50 to 45, expanding the eligible population by approximately 20 million adults. Compliance with the expanded recommendation has been slow — younger adults are less connected to primary care, less likely to have completed prior colonoscopies, and more likely to defer preventive care because of cost or scheduling barriers.

Into that gap, a blood test at a preventive-care visit is a much lower-friction ask than a colonoscopy referral. The test can be added to routine bloodwork. It requires no bowel preparation, no anaesthesia, no time off work. That friction reduction is where the public health argument for these tests lives.

Cross-layer implications

For primary care: Family medicine and internal medicine practices are now the front line for two FDA-approved blood tests with essentially equivalent performance and different pricing. Practice guidelines from the American College of Gastroenterology and the American Cancer Society will need updating within the next twelve months to address positioning.

For payors: Both tests are covered as ACA preventive services without cost-sharing. The direct comparative-effectiveness case will be built by insurers over the next 24 months based on real-world screening completion rates and downstream colonoscopy rates.

For gastroenterology capacity: A positive blood test result must be followed by a diagnostic colonoscopy. If blood testing expands the screened population meaningfully, the demand for diagnostic colonoscopy will rise. GI capacity in most US markets is already constrained, with wait times of 6–12 weeks common in urban centres.

For the two vendors: SimpleScreen enters a market Shield has had to itself for two years. Marketing, primary-care detailing, and payor negotiation are about to intensify. Both companies are burning capital.

What this means for you

If you are aged 45 or older and not up to date on colorectal cancer screening: talk to your primary care physician. Colonoscopy remains the most effective screen. If you will not or cannot do it, the blood test is now a reasonable alternative — and a much better option than skipping screening entirely.

If you have completed a colonoscopy in the last ten years and had a normal result: you do not need the blood test. Continue on your existing surveillance schedule.

If you have a family history of colorectal cancer or a personal history of polyps: the blood test is not for you. You are not in the "average-risk" category the test is approved for. Follow your specialist's schedule.

If you are a primary care physician: the two-test market changes the conversation. Have a clear default position on how you introduce and position the tests, and be explicit with patients that a positive result requires colonoscopy.

If you are caring for a family member who has resisted colonoscopy: this is the conversation to have. A blood draw is a lower-friction ask than a colonoscopy referral, and it is now a covered option.

Uncertainty ledger

Whether SimpleScreen's multiomic approach delivers real-world sensitivity above Shield's methylation-focused platform — head-to-head data does not exist.
The rate at which patients with positive blood tests actually complete follow-up colonoscopy — this determines the public health value.
Whether the tests displace or supplement colonoscopy in patients who would otherwise complete the gold-standard screen.
The long-term mortality-reduction data — will not be available for at least a decade given the follow-up required.
Pricing dynamics between Freenome and Guardant as they compete for payor contracts.

Bottom Line

The arrival of a second blood test for colorectal cancer widens a door that Shield opened two years ago. For the third of eligible Americans who do not currently get screened, that door leads to earlier cancer detection than they would otherwise receive — and that will save lives. For the two-thirds who do get screened, the blood test does not replace what colonoscopy already provides. The medicine is subtle: this is a triage tool, not a substitute. Whether it is used that way is now a matter of how primary care, payors, and patients respond over the next twenty-four months.

Sources

FDA approval letter for SimpleScreen CRC, 30 Jul 2026 (Tier 1 — primary)
Freenome press release and PREEMPT CRC pivotal trial data, presented DDW 2025 (Tier 1)
Medical News Today — coverage of the approval and clinician commentary, 4 Aug 2026 (Tier 2)
Memorial Sloan Kettering Cancer Center — Dr Robin Mendelsohn commentary via Medical News Today (Tier 1)
Pharmacy Times — coverage of blood-based CRC screening landscape, 3 Aug 2026 (Tier 2)
Guardant Health — Shield ECLIPSE trial data, published 2024 (Tier 1)
American Cancer Society — Cancer Facts & Figures 2026 (Tier 1)
US Preventive Services Task Force — colorectal cancer screening recommendation (2021 update) (Tier 1)